Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q424869> ?p ?o }
Showing triples 1 to 30 of
30
with 100 triples per page.
- Q424869 subject Q7335338.
- Q424869 subject Q7335370.
- Q424869 subject Q8297678.
- Q424869 subject Q8515266.
- Q424869 abstract "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma.MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.".
- Q424869 iupacName "N-(2-Aminophenyl)-4-(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide".
- Q424869 thumbnail Mocetinostat.png?width=300.
- Q424869 wikiPageWikiLink Q123251.
- Q424869 wikiPageWikiLink Q14914420.
- Q424869 wikiPageWikiLink Q18026859.
- Q424869 wikiPageWikiLink Q18033475.
- Q424869 wikiPageWikiLink Q18046437.
- Q424869 wikiPageWikiLink Q209369.
- Q424869 wikiPageWikiLink Q264118.
- Q424869 wikiPageWikiLink Q30612.
- Q424869 wikiPageWikiLink Q3569101.
- Q424869 wikiPageWikiLink Q417731.
- Q424869 wikiPageWikiLink Q7335338.
- Q424869 wikiPageWikiLink Q7335370.
- Q424869 wikiPageWikiLink Q8297678.
- Q424869 wikiPageWikiLink Q8515266.
- Q424869 iupacname "N--4-(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide".
- Q424869 type ChemicalCompound.
- Q424869 type ChemicalSubstance.
- Q424869 type ChemicalObject.
- Q424869 type Thing.
- Q424869 type Q11173.
- Q424869 comment "Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma.MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.".
- Q424869 label "Mocetinostat".
- Q424869 depiction Mocetinostat.png.